关键词: bone microarchitecture combination therapy fracture risk

Mesh : Absorptiometry, Photon Anabolic Agents / therapeutic use Antibodies, Monoclonal, Humanized / therapeutic use Bone Density Conservation Agents / therapeutic use Calcium / therapeutic use Denosumab Diphosphonates / therapeutic use Female Humans Magnetic Resonance Imaging Osteoporosis, Postmenopausal / diagnosis drug therapy Osteoporotic Fractures / prevention & control Risk Assessment Teriparatide / therapeutic use Tomography, X-Ray Computed Vitamin D / therapeutic use

来  源:   DOI:10.1146/annurev-med-070313-022841   PDF(Sci-hub)

Abstract:
A hallmark of menopause, which follows the decline in the ovarian production of estrogen, is the aggressive and persistent loss of bone mineral and structural elements leading to loss of bone strength and increased fracture risk. This review focuses on newer methods of diagnosing osteoporosis and assessing fracture risk, as well as on novel management strategies for prevention and treatment. Fracture-risk prediction has been significantly enhanced by the development of methods such as the trabecular bone score, which helps assess bone microarchitecture and adds value to standard bone densitometry, and the Fracture Risk Assessment Tool (FRAX) algorithm techniques. The treatment of osteoporosis, which has the goals of fracture prevention and risk reduction, is moving beyond traditional monotherapies with antiresorptives and anabolic agents into new combination regimens.
摘要:
更年期的标志,这是在卵巢雌激素产生下降之后,是骨矿物质和结构元素的侵袭性和持续性损失,导致骨强度损失和骨折风险增加。这篇综述的重点是诊断骨质疏松症和评估骨折风险的新方法。以及预防和治疗的新管理策略。骨小梁评分等方法的发展显着增强了骨折风险预测,这有助于评估骨骼微观结构,并为标准骨密度测定增加价值,和裂缝风险评估工具(FRAX)算法技术。骨质疏松症的治疗,其目标是预防骨折和降低风险,正在超越传统的单一疗法,包括抗吸收剂和合成代谢药物,进入新的联合治疗方案。
公众号